Overview

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Asana BioSciences